Purdue University researchers are developing a series of drug compounds to treat recurrence of acute myeloid leukemia (AML), an aggressive and deadly blood cancer. About 19,520 people are diagnosed with AML each year, and about 10,670 die from it, according to the American Cancer Society. About 30 percent of AML patients have an FLT3 enzyme mutation that makes the disease more aggressive. Patients treated with new drugs approved by the Food and Drug Administration (FDA) – Radapt and Gilteritinib, both FLT3 inhibitors – have shown good initial response to treating leukemia. But AML patients treated with FLT3 inhibitors often relapse ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.